The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size is expected to reach US$ 11190 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in various end use industries. The expanding demands from the Hospitals & Clinics, Home Settings and Ambulatory Surgical Centers (ASCs),, are propelling Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market. Oral Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Injectable Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics covered in this report include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, Segment by Type:
Oral Therapy
Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size is expected to reach US$ 11190 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in various end use industries. The expanding demands from the Hospitals & Clinics, Home Settings and Ambulatory Surgical Centers (ASCs),, are propelling Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market. Oral Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Injectable Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics covered in this report include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, Segment by Type:
Oral Therapy
Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics
1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview
1.1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Scope
1.1.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Status and Outlook
1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2029)
1.4 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market by Type
2.1 Introduction
2.1.1 Oral Therapy
2.1.2 Injectable Therapy
2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals & Clinics
3.1.2 Home Settings
3.1.3 Ambulatory Surgical Centers (ASCs)
3.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Competition Analysis by Players
4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2022)
4.3 Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
4.4 Global Top Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Headquarters and Area Served
4.5 Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Inc.
5.1.1 Astellas Inc. Profile
5.1.2 Astellas Inc. Main Business
5.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Inc. Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Johnson & Johnson Recent Developments
5.3 Sanofi S.A
5.3.1 Sanofi S.A Profile
5.3.2 Sanofi S.A Main Business
5.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Dendreon Corporation Recent Developments
5.4 Dendreon Corporation
5.4.1 Dendreon Corporation Profile
5.4.2 Dendreon Corporation Main Business
5.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Dendreon Corporation Recent Developments
5.5 Bayer AG
5.5.1 Bayer AG Profile
5.5.2 Bayer AG Main Business
5.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Bayer AG Recent Developments
6 North America
6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Dynamics
11.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industry Trends
11.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers
11.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
11.4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
